EBR is a phase 3 medtech company with breakthrough device...

EBR is a phase 3 medtech company with breakthrough device designation from the FDA. The final premarket approval could be submitted any day now.

If this were a drug company, with fast track designation from the FDA, effectively equivalent to breakthrough device designation for medical devices, and had completed phase 3 trials, its market capitalisation would be MUCH higher than EBR’s. In my opinion! Big pharma wouldn’t wait for FDA approval if they wanted to buy the company’s IP. They would just make an offer with a view to managing the regulatory process.

I can’t see why Abbott Labs, Medtronic, or Boston Scientific would wait for the regulators on this one, once the final PMA is submitted. It wouldn’t make sense, given the strategic fit of EBR’s IP with their own plans for constant innovation and ambitions for market dominance. EBR has been 20 years in the making. Now it’s coming to an exciting conclusion.

DYOR